Biosimilars are expected to drive the growth of the erythropoietin drug market

The global erythropoietin drug market is anticipated to grow at a considerable CAGR of around 5.6% during the forecast period. R&D departments of companies are working upon to develop biosimilar of erythropoietin drugs. They will prove a market driver in the forecast period as drugs by many pharmaceutical companies are costly. Treatment of chronic kidney disease, anemia caused by cancer needs erythropoietin drugs for increasing hemoglobin levels. Biosimilar will prove to be a low-cost alternative. They are easy to develop and require less time to gain approval as compared to biologics. Biologics are derived from living organisms such as humans, animals, microorganisms, or yeast. Characteristics, chemical identity, and bioactivity of biosimilars are compared with reference products by the state of the art technology. 

Browse the full report description of “Global Erythropoietin Drug Market Size, Share & Trends Analysis Report by Product type (Epoetin Alfa, Epoetin Beta, Darbepoetin-Alfa, and Others), By Application (Hematology, Kidney Disorders, Cancer, and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/erythropoietin-drug-market

As per the Food and Drug Administration of the US, a reference product is a biological product that has been already approved. Comparison is made between reference products and biosimilar products. For instance, in Feb 2022, Biocon biologics, which is a subsidiary of Biocon, announced that it is going to acquire  Viatris’ biosimilar business for $3.3 billion. Studies are conducted by medical research agencies and institutions which are showing positive results are also paving the way to an increase in biosimilar in coming times. For instance, in Feb 2022, a comparative study and analysis were made in between Pan Gen Biotech’s epoetin alfa biosimilar which was PDA10. The reference product was Epogen. Both the products saw equal efficacy and safety.   

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Product type

o By Application 

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Amgen Inc., Johnson & Johnson, Hospira Inc., F.Hoffman-La Roche AG, LG Chem, and others 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impact the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Erythropoietin Drug Market Report by Segment

By Product type 

• Epoetin alfa
• Epoetin beta 
• Darbepoetin-alfa

By Application

• Hematology
• Kidney Disorders
• Cancer

Global Erythropoietin Drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/erythropoietin-drug-market